SCHEMBL202188

SCHEMBL202188

CCCc1ccc(-c2ccc(C(=O)NC(CSC)C(=O)O)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 2/20 0.53
TAS1R1 Q7RTX1 2/20 0.53
PLK1 P53350 1/20 0.50
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
ACE P12821 1/20 0.48
POLB P06746 2/20 0.46
CTDSP1 Q9GZU7 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
CA2 P00918 4/20 0.46
CA1 P00915 2/20 0.46
CA12 O43570 1/20 0.46
CA9 Q16790 1/20 0.46
RARB P10826 2/20 0.44
CYP1A2 P05177 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
FNTA P49354 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL201285 0.89 CA2 (0.60) TAS1R3TAS1R1PLK1NPC1RAB9A
SCHEMBL203604 0.87 TAS1R3 (0.67) TAS1R3TAS1R1PLK1NPC1RAB9A
SCHEMBL203603 0.87 TAS1R3 (0.67) TAS1R3TAS1R1PLK1NPC1RAB9A
SCHEMBL201119 0.87 TAS1R3 (0.54) TAS1R3TAS1R1PLK1NPC1RAB9A
SCHEMBL201120 0.87 TAS1R3 (0.54) TAS1R3TAS1R1PLK1NPC1RAB9A
SCHEMBL2692851 0.87 TAS1R3 (0.54) TAS1R3TAS1R1PLK1NPC1RAB9A
SCHEMBL203618 0.82 TAS1R3 (0.51) TAS1R3TAS1R1PLK1NPC1RAB9A
SCHEMBL201383 0.81 CA2 (0.52) TAS1R3TAS1R1PLK1NPC1RAB9A
SCHEMBL4173638 0.80 TAS1R3 (0.76) TAS1R3TAS1R1PLK1POLBCTDSP1
SCHEMBL201891 0.79 L3MBTL1 (0.76) TAS1R3TAS1R1PLK1L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
EP-1963262-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
WO-2007069020-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 TAS1R3 1250/4885TAS1R1 1011/4885PLK1 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.